RCTs examining the effect of ACEI or ARB vs. placebo in patients with CKD and DM [categorical outcomes]. Supplementary Table 39. RCTs examining the effect of ACEI or ARB vs. placebo in patient with CKD and DM [continuous outcomes]. Supplementary Table 40. Evidence profile of RCTs examining the effect of ACEI or ARB vs. dihydropyridine CCB in patients with CKD and Type 2 DM. Supplementary Table 41. RCTs examining the effect of ACEI or ARB vs. dihydropyridine CCB in patients with CKD and Type 2 DM [categorical outcomes]. Supplementary Table 42. RCTs examining the effect of ACEI or ARB vs. dihydropyridine CCB in patients with CKD and Type 2 DM [continuous outcomes]. Supplementary Table 43. Evidence profile of RCTs examining the effect of ACEI vs. ARB in patients with Type 2 DKD. Supplementary Table 44. RCTs examining the effect of ACEI vs. ARB in microalbuminuric patients with CKD and Type 2 DM [categorical outcomes]. Supplementary Table 45. RCTs examining the effect of ACEI vs. ARB in microalbuminuric patients with CKD and Type 2 DM [continuous outcomes]. Supplementary Table 46. Evidence profile of RCTs examining the effect of ARB vs. ARB in patients with CKD and DM. Supplementary Table 47. RCTs examining the effect of ARB vs. ARB in overtly albuminuric patients with CKD and Type 2 DM [categorical outcomes]. Supplementary Table 48. RCTs examining the effect of ARB vs. ARB in overtly albuminuric patients with CKD and Type 2 DM [continuous outcomes]. Supplementary Table 49. RCTs examining the effect of DRI ARB vs. placebo ARB in microalbuminuric patients with CKD and Type 2 DM [continuous outcomes]. Supplementary Table 50. RCTs examining the effect of dihydropyridine CCB vs. placebo in overtly albuminuric patients with CKD and Type 2 DM [categorical outcomes]. Supplementary Table 51. 